104 related articles for article (PubMed ID: 3366218)
21. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients.
Bogni A; Cortinois A; Grasselli G; Seregni E; Crippa F; Castellani MR; Bombardieri E
J Biol Regul Homeost Agents; 1994; 8(4):121-5. PubMed ID: 7660854
[TBL] [Abstract][Full Text] [Related]
22. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
24. Relation between enzymatic activities and the degree of malignancy of human lymphomas.
Vezzoni P; Giardini R; Raineri M; Pozzi MR; Lucchini R; Vezzoni MA; Clerici L; Besana C; Rugarli C; Rilke F
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):945-50. PubMed ID: 4043177
[TBL] [Abstract][Full Text] [Related]
25. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma.
Legouffe E; Rodriguez C; Picot MC; Richard B; Klein B; Rossi JF; Commes T
Leuk Lymphoma; 1998 Oct; 31(3-4):351-7. PubMed ID: 9869199
[TBL] [Abstract][Full Text] [Related]
26. Noncutaneous T-cell lymphomas. Recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis.
de Bruin PC; Noorduyn AL; van der Valk P; van Heerde P; van Diest PJ; van de Sandt MM; Ossenkoppele GJ; Meijer CJ
Cancer; 1993 Apr; 71(8):2604-12. PubMed ID: 8453584
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of selected clinical prognostic factors in patients with non-granulomatous lymphomas].
Rolski J
Pol Merkur Lekarski; 1997 May; 2(11):324-6. PubMed ID: 9377682
[TBL] [Abstract][Full Text] [Related]
28. [Clinical and prognosis relevance of the Kiel classification of non-Hodgkin lymphomas].
Brittinger G; Engelhard M
Verh Dtsch Ges Pathol; 1992; 76():37-46. PubMed ID: 1283273
[TBL] [Abstract][Full Text] [Related]
29. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis.
Gronowitz JS; Bergström R; Nôu E; Påhlman S; Brodin O; Nilsson S; Källander CF
Cancer; 1990 Aug; 66(4):722-32. PubMed ID: 2167141
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and survival in non-Hodgkin's lymphomas: the experience of the Istituto Oncologico Romagnolo (IOR).
Pasquini E; Nicolini M; Rosti G; Amadori M; Pileri S; Nanni O; Fattori PP; Marangolo M; Amadori D; Ravaioli A
Leuk Lymphoma; 1994 Aug; 14(5-6):475-82. PubMed ID: 7812208
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in head and neck non-Hodgkin's lymphoma with special reference to serum lactic dehydrogenase and serum copper.
Hisamitsu S; Shibuya H; Hoshina M; Horiuchi J
Acta Oncol; 1990; 29(7):879-83. PubMed ID: 2261202
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic factors in low-grade lymphoma].
Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Zubizarreta A
Sangre (Barc); 1998 Jun; 43(3):185-90. PubMed ID: 9741223
[TBL] [Abstract][Full Text] [Related]
33. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
[TBL] [Abstract][Full Text] [Related]
34. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase.
Suki S; Swan F; Tucker S; Fritsche HA; Redman JR; Rodriguez MA; McLaughlin P; Romaguera J; Hagemeister FB; Velasquez WS
Leuk Lymphoma; 1995 Jun; 18(1-2):87-92. PubMed ID: 8580834
[TBL] [Abstract][Full Text] [Related]
35. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
[TBL] [Abstract][Full Text] [Related]
36. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
37. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
38. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas.
Ferraris AM; Giuntini P; Gaetani GF
Blood; 1979 Oct; 54(4):928-32. PubMed ID: 476306
[TBL] [Abstract][Full Text] [Related]
39. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia.
Musto P; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G; Modoni S; Parlatore L; Valvano MR; Carotenuto M
Br J Haematol; 1995 May; 90(1):125-30. PubMed ID: 7786774
[TBL] [Abstract][Full Text] [Related]
40. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
